There is considerable interest in the role of B cell dysfunction particularly as targeting B cells therapeutically with rituximab has been promising.[58] Ongoing clinical trials in SSc-ILD are looking at other B cell target approaches including CD19 chimeric antigen receptot T cell (CAR-T) therapy and belimumab. Here, CD19 is linked to systemic sclerosis.